Illegal use of beta-adrenergic agonists: European Community.
about
Differential gene expression profile in pig adipose tissue treated with/without clenbuterol.Food-borne clenbuterol may have potential for cardiovascular effects with chronic exposure (commentary).Sympathetic nerve activity in normal and cystic follicles from isolated bovine ovary: local effect of beta-adrenergic stimulation on steroid secretion.Analytical methods for the detection of clenbuterol.General Template for the FMEA Applications in Primary Food Processing.State of art of nanotechnology applications in the meat chain: A qualitative synthesis.Distinction of clenbuterol intake from drug or contaminated food of animal origin in a controlled administration trial - the potential of enantiomeric separation for doping control analysis.Urinary Excretion of the β-Adrenergic Feed Additives Ractopamine and Zilpaterol in Breast and Lung Cancer Patients.Effects of the β2 -agonist clenbuterol on testicular steroidogenic acute regulatory protein mRNA expression in adult rats.Determination of salbutamol using R-phycoerythrin immobilized on eggshell membrane surface as a fluorescence probe.A food safety control low mass-range proteomics platform for the detection of illicit treatments in veal calves by MALDI-TOF-MS serum profiling.Clenbuterol ingestion causing prolonged tachycardia, hypokalemia, and hypophosphatemia with confirmation by quantitative levels.Accumulation of ractopamine residues in hair and ocular tissues of animals during and after treatment.Synthesis of ractopamine molecularly imprinted membrane and its application in the rapid determination of three β-agonists in porcine urine samples.Possible role of dexamethasone in sensitizing the beta-2-adrenergic receptor system in vivo in calves during concomitant treatment with clenbuterol.Rapid immunoassay method for the determination of clenbuterol and salbutamol in blood.Accumulation of the beta(2)-adrenergic agonist clenbuterol in mouse dark hair.Nitrofurazone accumulates in avian eyes--a replacement for semicarbazide as a marker of abuse.Changes in lymphocyte glucocorticoid and beta-adrenergic receptors in veal calves treated with clenbuterol and steroid hormones for growth-promoting purposes.A paper-based competitive lateral flow immunoassay for multi β-agonist residues by using a single monoclonal antibody labelled with red fluorescent nanoparticles.Adverse analytical findings with clenbuterol among U-17 soccer players attributed to food contamination issues.Clenbuterol - regional food contamination a possible source for inadvertent doping in sports.
P2860
Q33307204-83963034-5170-4524-8CE0-10B885432A46Q34349754-8DB40C60-1920-413C-AB91-A16D875A4F3FQ35052912-4DD6B864-0AF7-4DAD-8997-50CBCB23C378Q37810202-9645E995-D5D7-403D-B73C-B3929EAAC032Q39165913-A163483D-4977-431F-9B29-DA9E87B5FA31Q39296020-F95E7AD1-05CD-4452-A92D-158BB4E76978Q39333685-BB1CD50A-D72E-4B93-9E37-D8273EBCFD60Q39376575-252B33CA-3336-4908-B134-C68A79CD8468Q42826540-0CAF319F-611C-441B-BDE5-109CCC80AA61Q43015939-E63CA359-0590-40DD-B2DA-4B27FF885A72Q43310755-CD0A0C40-E109-4CA6-9D94-FA5EC9103A51Q43722860-7C1BA820-862F-496A-9371-8D3EBA4D22E8Q43967510-5474D96A-C72E-4959-80F6-4AEBF9A44A29Q44949034-85FA99CA-EED4-4B79-8F84-1C519D01B8A9Q45081559-9525FAD3-F3C5-4A6E-8896-AF09E6EFADF8Q45372492-EC72822E-97F3-4913-83B2-E6EBF8A3D74DQ45966346-8957B695-E219-4732-94BF-E18D425A8545Q46506111-8C961646-A624-401C-BC83-1B58B31ABCA1Q46974280-DBCB0998-987B-498D-A211-7FD47AD03743Q50317891-3E798E34-C42A-4CE7-9037-CE67F7264E88Q50861639-C6F5A861-7585-42A8-8DF9-81E10317C202Q53133101-732F4EA5-AE86-4AF2-8A46-65E220948F62
P2860
Illegal use of beta-adrenergic agonists: European Community.
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Illegal use of beta-adrenergic agonists: European Community.
@ast
Illegal use of beta-adrenergic agonists: European Community.
@en
Illegal use of beta-adrenergic agonists: European Community.
@nl
type
label
Illegal use of beta-adrenergic agonists: European Community.
@ast
Illegal use of beta-adrenergic agonists: European Community.
@en
Illegal use of beta-adrenergic agonists: European Community.
@nl
prefLabel
Illegal use of beta-adrenergic agonists: European Community.
@ast
Illegal use of beta-adrenergic agonists: European Community.
@en
Illegal use of beta-adrenergic agonists: European Community.
@nl
P2093
P356
P1476
Illegal use of beta-adrenergic agonists: European Community.
@en
P2093
Noordam MY
van Dooren-Flipsen MM
P304
P356
10.2527/1998.761195X
P407
P577
1998-01-01T00:00:00Z